Connecticut is currently home to 1244 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Haven, Hartford, Farmington and Stamford. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer
Recruiting
The purpose of this study is to compare any good or bad effects of using pembrolizumab (an experimental drug) and radiation therapy (RT), compared to using cisplatin chemotherapy and radiation therapy (RT) in the treatment of patients with head and neck squamous cell carcinoma (HNSCC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/02/2024
Locations: Yale Cancer Center, New Haven, Connecticut
Conditions: Head and Neck Squamous Cell Carcinoma, Cancer, Cancer of Head and Neck, Cancer, Advanced, Cancer, Metastatic, Tumor, Tumor Recurrence, Tumor Neck, Tumor Metastasis, Oral Cancer, Oropharyngeal Cancer, Oropharynx Cancer, Oropharynx Cancer, Stage III, Oropharynx Cancer, Recurrent, Oropharynx Cancer, Metastatic
Systems Investigation of Vaccine Responses in Aging and Frailty
Recruiting
This study will compare the immune response signatures (including immunologic, transcriptomic and metabolomic) of the two influenza vaccines approved for use in adults age 65 and over (Fluad and Fluzone High-Dose).
Gender:
ALL
Ages:
21 years and above
Trial Updated:
08/01/2024
Locations: Yale School of Medicine, New Haven, Connecticut
Conditions: Influenza
Effect of TXA Oral Sol 5% in Patients Treated With DOACs or VKA and Undergoing a Single or Multiple Tooth Extraction
Recruiting
The purpose of this study is to assess the effect of Tranexamic Acid Oral Solution 5% in patients treated with direct oral anticoagulants or vitamin K antagonists and undergoing a single or multiple tooth extraction.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
07/31/2024
Locations: Stamford Therapeutics Consortium, Stamford, Connecticut
Conditions: Bleeding From Teeth, Bleeding Prophylaxis
Song-making In a Group (SING)
Recruiting
The overarching aim of the proposed work is to align a promising treatment lead - Musical Intervention (MI) - with a promising mechanistic account of psychosis - Predictive Processing. This protocol focuses on the R33 phase, to optimize its administration (Is active participation more effective than passive listening? Does creation of new music help more than performing others' creations?). By tracking the interrelation between symptom mechanisms and MI, the investigators can use those metrics t... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/30/2024
Locations: Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut
Conditions: Schizophrenia
A Multiple Ascending Dose Study in Healthy Volunteers and Patients With Alzheimer's Disease
Recruiting
A Phase 1b Multiple Ascending Dose Study of the Safety and Tolerability of BMS-984923 in Healthy Older Adults and Patients with Alzheimer's Disease
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
07/29/2024
Locations: Yale University, New Haven, Connecticut
Conditions: Alzheimer's Disease
ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2
Recruiting
This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinical remission in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies \[corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)\] and/or advanced therapies \[biologics (TNF inhibitors, anti-integrin... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
07/25/2024
Locations: Danbury Hospital, Danbury, Connecticut
Conditions: Ulcerative Colitis
Expanding Medication-Assisted Therapies in Central Asia
Recruiting
Central Asia (CA) represents the most rapidly growing HIV epidemic region worldwide, concentrated in people who inject drugs (PWID) and their sexual partners, and scaling up opioid agonist therapies (OAT) in this region is the most cost-effective strategy to prevent new HIV infections, and more effective when combined with antiretroviral therapy (ART). The investigators propose to use the Network for the Improvement of Addiction Treatment (NIATx) implementation strategy to scale-up OAT in three... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2024
Locations: Yale University, New Haven, Connecticut
Conditions: Opioid Use Disorder
Prospective Data Registry and Quality of Life Assessment of Patients Undergoing Radiotherapy With the RefleXion Medical Radiotherapy System
Recruiting
The purpose of this prospective cohort study is to assess clinical and quality of life measures as well as to define the severity of adverse effects for the use of the RefleXion system to deliver intensity-modulated radiotherapy (IMRT), stereotactic body radiotherapy (SBRT), or SCINTIX Biology-guided radiotherapy (BgRT) in standard of care (SOC) use in the treatment of local,loco-regionally advanced, and oligometastatic malignancies. In addition, patient costs and charges will be analyzed to qua... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/24/2024
Locations: Yale University - Cancer Center, New Haven, Connecticut
Conditions: Cancer, Cancer Central Nervous System, Cancer Thoracic, Cancer, Gastrointestinal, Cancer Gynecologic, Cancer, Genito-Urinary, Cancers Lymphatic, Cancer Head and Neck
Vitamin D in OUD: Exploration of Alterations on the Dopamine D2/D3 Receptor System
Recruiting
The research team is investigating Opioid Use Disorder (OUD), a disorder characterized by dysregulated dopaminergic tone, to evaluate the mechanisms of adjunctive treatment with calcitriol. The investigators will recruit 12 subjects with OUD and 12 healthy subjects to participate in a double-blind, randomized study design where subjects will complete up to 2 Positron Emission Tomography (PET) scans using \[11C\]-PHNO. The investigators will compare subjects in differences between their own study... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
07/22/2024
Locations: Yale School of Medicine, New Haven, Connecticut
Conditions: Opioid Use Disorder
BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors
Recruiting
The goal of this first in human clinical trial is to test BI-1910 administered as single agent and in combination with pembrolizumab in subjects with advanced/metastatic solid tumors whose disease has progressed after standard therapy. The main questions it aims to answer are: * how safe and tolerable is BI-1910 * what is maximum tolerated or administrated dose * to determine recommended dose for further clinical trials Participants will receive infusions of BI-1910 alone or combination with... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2024
Locations: Yale Cancer Center, New Haven, Connecticut
Conditions: Solid Tumors, Non Small Cell Lung Cancer, Hepatocellular Carcinoma
Pharmacological and Behavioral Treatment After Bariatric Surgery: Acute (Stage 1)
Recruiting
This study will compare the effectiveness of behavioral and pharmacologic treatments, alone and in combination, for the treatment of loss-of-control eating and weight following bariatric surgery. This is an acute treatment comparing behavioral weight loss alone or in combination with combination naltrexone/bupropion medication.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/22/2024
Locations: Yale Department of Psychiatry, New Haven, Connecticut
Conditions: Loss-of-control Eating, Obesity/Overweight
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Recruiting
This study is designed to estimate the efficacy and toxicity of familial HLA mismatched bone marrow transplants in patients with non-malignant disease who are less than 21 years of age and could benefit from the procedure.
Gender:
ALL
Ages:
Between 1 day and 21 years
Trial Updated:
07/22/2024
Locations: Yale School of Medicine, New Haven, Connecticut
Conditions: Severe Sickle Cell Disease, Bone Marrow Failure Syndromes, Metabolic Disorders, Immunologic Disorders, Hemoglobinopathies, Non-malignant Disorders